March 31, 2017

Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer

Phase 2 pilot PANOVA data presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls… Read More
learn more
March 31, 2017

Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer

Phase 2 pilot INNOVATE data will be presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–… Read More
learn more
March 31, 2017

Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer

Phase 2 pilot PANOVA data presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls… Read More
learn more
March 31, 2017

Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer

Phase 2 pilot INNOVATE data will be presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–… Read More
learn more
March 31, 2017

Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma

Interim results from the STELLAR trial, presented in December 2016, suggest improvements in progression free survival and one-year survival rates when TTFields is added to standard chemotherapy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the STELLAR trial, a… Read More
learn more
March 31, 2017

Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma

Interim results from the STELLAR trial, presented in December 2016, suggest improvements in progression free survival and one-year survival rates when TTFields is added to standard chemotherapy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the STELLAR trial, a… Read More
learn more
March 28, 2017

Novocure to Report First Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2017 on Thursday, April 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months… Read More
learn more
March 28, 2017

Novocure to Report First Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2017 on Thursday, April 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months… Read More
learn more
March 28, 2017

Novocure to Present at the 16th Annual Needham & Company Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 16th Annual Needham & Company Healthcare Conference on April 5, 2016, in New York. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More
learn more
March 28, 2017

Novocure to Present at the 16th Annual Needham & Company Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 16th Annual Needham & Company Healthcare Conference on April 5, 2016, in New York. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More
learn more